1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Ticagrelor was approved for use in the EU in December 2010 (AstraZeneca, press release, December 6, 2010) under the brand name Brilique. In July 2011, the FDA approved ticagrelor for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the acute phase of ACS, along with standard aspirin therapy, at a loading dose of 180mg. During the chronic treatment phase, 90mg doses are taken twice daily with maintenance doses of aspirin not to exceed 100mg.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 18
3.1.3 Prognosis 19
3.1.4 Quality of Life 20
3.2 Symptoms 20
4 Disease Management 22
4.1 Treatment Overview 22
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Brilinta (ticagrelor) 34
6.1 Overview 34
6.2 Efficacy 35
6.3 Safety 36
6.4 SWOT Analysis 37
6.5 Forecast 37
7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 44
7.3 Methodology 48
7.4 Forecasting Methodology 48
7.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 48
7.4.2 Diagnosed Acute Coronary Syndrome Patients 49
7.4.3 Percent Drug-Treated Patients 50
7.4.4 General Pricing Assumptions 50
7.4.5 Individual Drug Assumptions 52
7.4.6 Generic Erosion 52
7.5 Physicians and Specialists Included in this Study 53
7.6 About the Authors 56
7.6.1 Author 56
7.6.2 Reviewer 56
7.6.3 Global Head of Healthcare 57
7.7 About GlobalData 58
7.8 Disclaimer 58

1.1 List of Tables

Table 1: Antiplatelet Agents that Inhibit Platelet Activation 16
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade 16
Table 3: Symptoms of Acute Coronary Syndrome 21
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 25
Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014 27
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014 33
Table 7: Product Profile - Brilinta (ticagrelor) 35
Table 8: Brilinta (ticagrelor) SWOT Analysis, 2014 37
Table 9: Global Sales Forecasts ($m) for Brilinta, 2013-2023 38
Table 10: Price Sources and Calculations, by Country 51
Table 11: Physicians Surveyed, By Country 55

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 14
Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome 15
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 17
Figure 4: Electrocardiography in the Diagnosis of ACS 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.